Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 323: H10 Stabilized Stem Ferritin Vaccine in Healthy Adults
NCT04579250Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of VRC-FLUNPF0103-00-VP in influenza (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms and 5 more. Started Oct 2020; status: completed.
02
Drugs
VRC-FLUNPF0103-00-VP
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04579250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04579250.